Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;13(7):1859-1881.
doi: 10.1007/s13346-022-01233-3. Epub 2022 Sep 12.

Nanomaterials for antigen-specific immune tolerance therapy

Jinwon Park #  1 , Yina Wu #  1 , Qiaoyun Li  1 , Jaehyun Choi  1 , Hyemin Ju  1 , Yu Cai  2 , Jaiwoo Lee  1 , Yu-Kyoung Oh  3
Affiliations
Review

Nanomaterials for antigen-specific immune tolerance therapy

Jinwon Park et al. Drug Deliv Transl Res. 2023 Jul.

Abstract

Impairment of immune tolerance might cause autologous tissue damage or overactive immune response against non-pathogenic molecules. Although autoimmune disease and allergy have complicated pathologies, the current strategies have mainly focused on symptom amelioration or systemic immunosuppression which can lead to fatal adverse events. The induction of antigen-specific immune tolerance may provide therapeutic benefits to autoimmune disease and allergic response, while reducing nonspecific immune adverse responses. Diverse nanomaterials have been studied to induce antigen-specific immune tolerance therapy. This review will cover the immunological background of antigen-specific tolerance, clinical importance of antigen-specific immune tolerance, and nanomaterials designed for autoimmune and allergic diseases. As nanomaterials for modulating immune tolerances, lipid-based nanoparticles, polymeric nanoparticles, and biological carriers have been covered. Strategies to provide antigen-specific immune tolerance have been addressed. Finally, current challenges and perspectives of nanomaterials for antigen-specific immune tolerance therapy will be discussed.

Keywords: Allergic disease; Autoimmune disease; Nanomaterials; Nanoparticles; Tolerogenic vaccine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18:716–24. - PubMed - PMC
    1. Hodson R. Autoimmune disease. Nature. 2021;595:S45.
    1. Bochner BS, Rothenberg ME, Boyce JA, Finkelman F. Advances in mechanisms of allergy and clinical immunology in 2012. J Allergy Clin Immunol. 2013;131:661–7. - PubMed
    1. Vercelli D. Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol. 2008;8:169–82. - PubMed
    1. Ronchetti S, Ayroldi E, Ricci E, Gentili M, Migliorati G, Riccardi C. A glance at the use of glucocorticoids in rare inflammatory and autoimmune diseases: still an indispensable pharmacological tool? Front Immunol. 2021;11: 613435. - PubMed - PMC

Publication types

LinkOut - more resources